2025-12-16 LIDR Meeting Notes
Date
Dec 16, 2025
Attendees
Bolded names indicates attendance
Name | Organization |
|---|---|
Hung Luu | Children’s |
Riki Merrick | Vernetzt, APHL |
Andrea Pitkus | University of Wisconsin |
Pam Banning | 3M - Solventum |
Xavier Gansel | Biomerieux |
Amy McCormick | Epic |
Dan Rutz | Epic |
Rob Rae | CAP |
Rob Hausam | Hausam Consulting |
Stan Huff | University of Utah |
Ed Heierman - regrets | Abbott / IICC |
Carmen Pugh | long term lab professional |
Laurent Lardin | Biomerieux |
Ralf Herzog | Roche |
Christina Gallegos | APHL |
Kathleen Figetakis | WA DOH |
Marti Velezis | Sonrisa / FDA |
|
|
|
|
Follow up on UDI representation |
Notes:
|
Next call | Tuesday Jan 13, 2026 9 - 10 AM ET |
Chat
Andrea Pitkus 9:10 AM
Are these data needed for a subset of reportables? If so, which ones?
Xavier Gansel 9:11 AM
data collected are simiar to UDI-DI content
manufacturer + ssytem / test kit brand name (i.e. identifier)
the rest is UDI - PI
Andrea Pitkus 9:12 AM
LOINC is proposing to remove screening and confirmatory from the LOINC method. Given you need to distinguish confirmatory versus screening assays, would this still be needed by you? The LOINC discussion has been focused on a Canadian research request to distinguish by method such as GC/MS, LC/MS, Immunoassay and that is the proposed change.
Andrea Pitkus 9:15 AM
Which are required by Washington state since it is exempt from CLIA and has some different requirements?
Andrea Pitkus 9:16 AM
Although labs in WA accredited would need to meet the requirements of their accreditor
Action items